From: A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
Age, median (range) (years)
57 (46–75)
Performance status, n
0
15
1
4
≥ 2
Histology, n
High-grade serous
12
Endometrial
Clear cell
Others
2
Previous platinum-based chemotherapy
14
5
Platinum-free interval (months)
7
1–2
3–4
6